Pharmaceutical Technology4 天
NUC-7738 by NuCana for Lung Adenocarcinoma: Likelihood of Approval
NUC-7738 is under clinical development by NuCana and currently in Phase II for Lung Adenocarcinoma. According to GlobalData, Phase II drugs for Lung Adenocarcinoma does not have sufficient historical ...
The American Journal of Managed Care1 天
FDA Approves First Subcutaneous Nivolumab Injection in Most Solid Tumors
FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.
ahmedabadmirror16 天
Why are non-smokers getting lung cancer?
Lung cancer, long known to affect smokers, is seeing a significant rise in people who do not smoke, said doctors, raising ...
Pharmaceutical Technology4 天
Tevimbra by BeiGene for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval
Tevimbra is under clinical development by BeiGene and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC).
来自MSN15 小时
Hanx Biopharmaceuticals doses first subject in trial of therapy for solid tumours
Hanx Biopharmaceuticals chairman Dr Faming Zhang said: "We are thrilled to see the first patient entered into a clinical ...
Cure Today7 天
Subcutaneous Opdivo Receives FDA Approval for Advanced, Metastatic Solid Tumors
Opdivo Qvantig is approved for solid tumors, including melanoma, renal cell carcinoma, and non-small cell lung cancer. The ...
Cancer Therapy Advisor4 天
Opdivo Qvantig Approved to Treat Solid Tumor Malignancies
The FDA has approved subcutaneous nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) to treat a range of solid tumor malignancies.